Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: Long-term impact and risk factors

American Journal of Transplantation

Volumn 9, Issue 3, 2009, Pages 567-577

  Toki, D ^a   Ishida, H ^a   Setoguchi, K ^a   Shimizu, T ^a   Omoto, K ^a   Shirakawa, H ^a   Iida, S ^a   Horita, S ^a   Furusawa, M ^a   Ishizuka, T ^a   Yamaguchi, Y ^b   Tanabe, K ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ABO incompatibility; Anti HLA antibodies; Mycophenolate mofetil; Transplant glomerulopathy

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN G;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODIES; BLOOD GROUP INCOMPATIBILITY; CREATINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; RISK FACTORS;

EID: 60649108279     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02538.x     Document Type: Article

References (45)

1. Tanabe K, Takahashi K, Sonda K et al. Clinicopathological analysis of rejection episodes in ABO-incompatible kidney transplantation. Transplant Proc 1996 28 : 1447 1448.
2. Toma H, Tanabe K, Tokumoto T. Long-term outcome of ABO-incompatible renal transplantation. Urol Clin North Am 2001 28 : 769 780.
3. Ishida H, Miyamoto N, Shirakawa H et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation-single center analysis. Am J Transplant 2007 7 : 825 831.
4. Tanabe K, Ishikawa N, Tokumoto T et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: A single-center experience. Transplant Proc 1998 30 : 1224 1226.
5. Futagawa Y, Terasaki P. ABO incompatible kidney transplantation - An analysis of UNOS Registry data. Clin Transplant 2006 20 : 122 126.
6. Takahashi K, Saito K. Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006 13 : 118 122.
7. Shimmura H, Tanabe K, Ishida H et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005 80 : 985 988.
8. Gloor J, Lager D, Fidler M et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005 80 : 1572 1577.
9. Gloor J, Cosio F, Rea D et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006 6 : 1841 1847.
10. Setoguchi K, Ishida H, Shimmura H et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008 8 : 86 94.
11. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000 70 : 1331 1335.
12. Gloor J, Lager D, Moore S et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003 75 : 971 977.
13. Tanabe K, Tokumoto T, Ishida H et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 2004 36 : 2175 2177.
14. Agishi T, Kaneko I, Hasuo Y et al. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 1980 26 : 406 411.
15. Ishida H, Tanabe K, Furusawa M et al. Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - Examination of 238 cases of renal transplantation. Transpl Int 2005 18 : 163 168.
16. Racusen L, Halloran P, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004 4 : 1562 1566.
17. Fidler M, Gloor J, Lager D et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004 4 : 101 107.
18. Takemoto S, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004 4 : 1033 1041.
19. Haas M, Rahman M, Racusen L et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006 6 : 1829 1840.
20. Racusen L, Solez K, Colvin R et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
21. Warren D, Zachary A, Sonnenday C et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004 4 : 561 568.
22. Tydén G, Kumlien G, Genberg H et al. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplantation 2006 13 : 105 107.
23. Tanabe K, Ishida H, Omoto K, Shimizu T, Shirakawa H. Antibody-mediated rejection: A single center experience at Tokyo Women's Medical University. Clin Transpl 2006 363 369.
24. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 2001 16 : 897 904.
25. Gebel H, Bray R, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003 3 : 1488 1500.
26. Süsal C, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004 65 : 810 816.
27. Muro M, Llorente S, Gónzalez-Soriano M, Minguela A, Gimeno L, Alvarez-López M. Pre-formed donor-specific alloantibodies (DSA) detected only by luminex technology using HLA-coated microspheres and causing acute humoral rejection and kidney graft dysfunction. Clin Transpl 2006 379 383.
28. Rodríguez L, París S, Arbeláez M et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007 68 : 652 660.
29. Campos E, Tedesco-Silva H, Machado P, Franco M, Medina-Pestana J, Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006 6 : 2316 2320.
30. Gloor J, Sethi S, Stegall M et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007 7 : 2124 2132.
31. Langan L, Park L, Hughes T et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007 7 : 847 856.
32. Gloor J, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004 78 : 221 227.
33. van den Berg-Loonen E, Billen E, Voorter C et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008 85 : 1086 1090.
34. Zhang Q, Liang L, Gjertson D, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005 79 : 591 598.
35. Gibney E, Cagle L, Freed B, Warnell S, Chan L, Wiseman A. Detection of donor-specific antibodies using HLA-coated microspheres: Another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006 21 : 2625 2629.
36. Lefaucheur C, Nochy D, Hill G et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007 7 : 832 841.
37. Lefaucheur C, Suberbielle-Boissel C, Hill G et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008 8 : 324 331.
38. Patel A, Pancoska C, Mulgaonkar S, Weng F. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007 7 : 2371 2377.
39. Ishida H, Koyama I, Sawada T et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: Survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000 70 : 681 685.
40. Smith K, Isbel N, Catton M, Leydon J, Becker G, Walker R. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998 13 : 160 164.
41. Rentenaar R, van Diepen F, Meijer R et al. Immune responsiveness in renal transplant recipients: Mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002 62 : 319 328.
42. Rose M, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002 21 : 282 285.
43. Ishida H, Tanabe K, Furusawa M et al. Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity. Transplantation 2002 74 : 1187 1189.
44. Sonnenday C, Warren D, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004 4 : 1315 1322.
45. Becker Y, Becker B, Pirsch J, Sollinger H. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 4 : 996 1001.